Aspirin effervescent tablets

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

The main ingredient of this product is aspirin. Its chemical name is 2-(acetoxy)benzoic acid. Molecular formula: C9H8O4 Molecular weight: 180.16

This product is white tablets.

It is used to treat fever caused by the common cold or influenza in children, and is also used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea.

Oral administration after dissolving in warm water. For children under 12 years old, see the following table for dosage: Age (years) Weight (kg) Dosage (tablets) Number of times per day 1-3 10-15 0.5-1 If fever or pain persists, 4-6 16-2 11.5-2 Can be taken at intervals of 4 to 6 hours Weight 7-9 22-27 2-2.5 Repeated use 1 time, 24 hours <

1 Common gastrointestinal reactions include nausea, vomiting, upper abdominal discomfort or pain. 2 Less common or rare reactions include (1) gastrointestinal bleeding or ulcers, manifested as bloody or tarry stools, severe stomach pain or vomiting of bloody or coffee-like substances, which are more common in patients taking large doses of the drug. (2) Bronchospasm-induced allergic reactions, manifested as dyspnea or asthma. (3) Skin allergic reactions, manifested as rash, urticaria, itchy skin, etc. (4) Hematuria, dizziness and liver damage.

1. Patients with asthma, nasal polyposis syndrome, and allergies to aspirin and other antipyretic analgesics are contraindicated. 2. Patients with hemophilia, thrombocytopenia, and active ulcer disease are contraindicated.

Precautions for children: Pediatric patients, especially those with fever and dehydration, are prone to toxic reactions. Acute febrile diseases, especially influenza and chickenpox, may be associated with Reye's syndrome when using this product. Severe cases may be fatal, which is rare in China. Precautions for pregnancy and lactation: Avoid use as much as possible. (1) This product easily crosses the placenta. Animal experiments have shown that the use of this product in the first three months of pregnancy can cause teratogenesis, such as spina bifida, skull cleft, facial cleft, leg deformity, and incomplete development of the central nervous system, internal organs and bones. There are also reports of fetal defects in humans after using this product. In addition, long-term and large-scale use of this product in the last three months of pregnancy can prolong the pregnancy period and increase the risk of post-term labor syndrome and antepartum hemorrhage. Use in the last two weeks of pregnancy can increase the risk of fetal hemorrhage or neonatal hemorrhage. Long-term use of the drug in the late pregnancy may also cause constriction or early closure of the fetal ductus arteriosus, leading to persistent pulmonary hypertension and heart failure in the newborn. It has been reported that excessive use or abuse of this drug in late pregnancy has increased the incidence of stillbirth or neonatal death (possibly due to ductus arteriosus occlusion, antepartum hemorrhage or low body weight). However, the above adverse reactions have not been found when using general therapeutic doses. (2) This product can be excreted in breast milk. When lactating women take 650 mg orally, the drug concentration in breast milk can reach 173-483 μg/ml after 5-8 hours. Therefore, long-term high-dose use may cause adverse reactions in infants. Precautions for the elderly: Elderly patients are prone to toxic reactions due to decreased renal function when taking this product, so the dose should be reduced.

1 This product should not be used with anticoagulants (such as dicoumarol, heparin) and thrombolytic drugs (streptokinase). 2 Antacids such as sodium bicarbonate can increase the excretion of this product in urine, causing a decrease in blood drug concentration, and should not be used together. 3 This product can increase gastrointestinal adverse reactions when used with glucocorticoids (such as dexamethasone, etc.). 4 This product can enhance the effects of oral hypoglycemic drugs and methotrexate, and should not be used together. 5 If used with other drugs at the same time, drug interactions may occur. Please consult a physician or pharmacist for details.

Keep tightly closed in a dry place.

0.3g

24 months

AstraZeneca Pharmaceutical Co., Ltd.

• Founded in:

  1993-10-26

• Address:

  No. 2 Huangshan Road, New District, Wuxi

• Tax NO.:

  91320214607915071G

• Registered Funds:

  $191.2 million

• Email:

  Log in to view